![]() Although the symptoms are often mild, myocarditis remains an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people less than 35 years old. Myocarditis is an acute inflammatory condition of the myocardium, characterized by inflammation of the heart muscle, which may result in chest pain, impaired cardiac function, atrial and ventricular arrhythmias, and conduction disturbances. ![]() Food and Drug Administration (FDA) providing clearance to proceed with the Company's Investigational New Drug (IND) application to commence this trial, as announced by the Company on August 24 th, 2021. ( NASDAQ: CRDL) ( TSX: CRDL) (" Cardiol" or the " Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that it has received approval from Health Canada to proceed with the Company's Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRxâ„¢ as well as its impact on myocardial recovery in patients presenting with acute myocarditis. October 25, 2021) - Cardiol Therapeutics Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |